Buscar en
Medicina de Familia. SEMERGEN
Toda la web
Inicio Medicina de Familia. SEMERGEN La microalbuminuria como factor de riesgo cardiovascular
Información de la revista
Vol. 30. Núm. 3.
Páginas 110-113 (Marzo 2004)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 30. Núm. 3.
Páginas 110-113 (Marzo 2004)
DOI: 10.1016/S1138-3593(04)74285-9
Acceso a texto completo
La microalbuminuria como factor de riesgo cardiovascular
Visitas
...
A. Calvo Cebriána,
Autor para correspondencia
antonio.calvo@ozu.es

Correspondencia: A. Calvo Cebrián. C/ Estiradores, 3, 3°B. 40002 Segovia
, N. Monge Roperob, R. Gómez Morenoc, M. Cruz Arnésd
a Médico de Familia. Médico de refuerzo. Centro de Salud. Galapagar. Área VI. Madrid
b Médico de Familia. Médico de refuerzo. Segovia
c Medico de Familia. Médico de refuerzo. Mallorca
d Médico de Familia. Centro de Salud. Galapagar. Área VI. Madrid
Información del artículo

La microalbuminuria como hallazgo clínico, se considera un marcador del daño orgánico renal en el paciente diabético. Además, su tratamiento en este tipo de pacientes ha demostrado una disminución en la progresión de la nefropatía diabética. En el presente trabajo, se realiza una revisión bibliográfica para intentar resolver hasta que punto se considera a la microalbuminuria un factor de riesgo cardiovascular, si sería correcto hacer determinaciones a la población general y si un tratamiento posterior mejoraría bien el riesgo cardiovascular o bien el pronóstico de los que presenten ya en algún grado la enfermedad cardiovascular.

Palbras clave:
microalbuminuria
factor
cardiovascular

Microalbuminuria as a clinical finding is considered a marker of renal organic injury in the diabetic patient. In addition, its treatment in this type of patients has demonstrated a decrease in the progression of diabetic nephropathy. In the present study, a bibliographic review is performed to try to resolve up to what point microalbuminuria is considered a cardiovascular risk factor, if it would be correct to make determinations in the general population and if a posterior treatment would well improve the cardiovascular risk or the prognosis of those who already present cardiovascular disease in some grade.

Key words:
microalbuminuria
factor
cardiovascular
El Texto completo está disponible en PDF
Bibliografía
[1.]
C.E. Mogensen, E. Vestbo, P.L. Poulsen, C. Christiansen, E.M. Damsgaard, H. Eiskjaer, et al.
Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion.
Diabetes Care, 18 (1995), pp. 572-581
[2.]
Y. Nakamura, B.D. Myers.
Charge selectivity of proteinuria in diabetic glomerulopathy.
Diabetes, 37 (1988), pp. 1202-1211
[3.]
P. Fioretto, M.W. Steffes, S.M. Mauer.
Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria.
Diabetes, 43 (1994), pp. 1358-1364
[4.]
J. Abellán, F. Hernández, J.A. García-Galbis, J.B. Gómez, J. Madrid, A. Martinez, et al.
Los nuevos factores de riesgo cardiovascular.
Hipertensión, 4 (2001), pp. 171-185
[5.]
M. Roest, J.D. Banga, W.M.T. Janssen, D.E. Grobbee, J.J. Sixma, P.E. de Jong, et al.
Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women.
Circulation, 103 (2001), pp. 3057-3061
[6.]
H.C. Gerstein, J.F. Mann, Q. Yi, B. Zinman, S.F. Dinneen, B. Hoogwerf, et al.
Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.
JAMA, 286 (2001), pp. 421-426
[7.]
J. Bonet, J. Vila, M.J. Alsina, L. Ancochea, R. Romero.
Prevalencia de microalbuminuria en la población general de un área mediterránea española y su asociación con otros factores de riesgo cardiovascular.
Med Clin (Barc), 116 (2001), pp. 573-574
[8.]
W.F. Terpstra, J.F. May, A.J. Smit, P.A. de Graeff, H.J. Crijns.
Microalbuminuria is related to marked end organ damage in previously untreated, elderly hypertensive patients.
Blood Press, 11 (2002), pp. 84-90
[9.]
G.F. Diercks, A.J. van Boven, H.L. Hillege, W.M. Jansen, J.A. Kors, P.E. de Jong, et al.
Microalbuminuria is independently associated with ischaemic electrocardiographic abnormalities in a large non-diabetic population. The PREVEND (Prevention of Renal and Vascular Endstage Disease) study.
Eur Heart J, 21 (2002), pp. 1922-1927
[10.]
F.C. Luft, B. Agrawal.
Microalbuminuria as a predictive factor for cardiovascular events.
J Cardiovasc Pharmacol, 33 (1999), pp. 11-15
[11.]
L.M. Ruilope.
Prevalence of renal disease in elderly hypertensive patients with cardiovascular problems.
Coron Artery Dis, 8 (1997), pp. 483-488
[12.]
B. Agrawal, A. Berger, K. Wolf, F.C. Luft.
Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension.
J Hypertens, 14 (1996), pp. 223-228
[13.]
E.K. Hoogeveen, P.J. Kostense, A. Jager, R.J. Heine, C. Jakobs, L.M. Bouter, et al.
Serum Homocysteine level and protein intake are related to risk of microalbuminuria: The Hoorm Study.
Kidney Int, 54 (1998), pp. 203-209
[14.]
T.B. Monster, W.M. Janssen, P.E. de Jong, L.T. de Jong-van den Berg.
Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria.
Arch Intern Med, 161 (2001), pp. 2000-2005
[15.]
M. Ravid, R. Lang, R. Rachmani, M. Lishner.
Long-Term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin dependent diabetes mellitus.
Arch Intern Med, 156 (1996), pp. 286-289
[16.]
M. Ravid, D. Brosh, Z. Levi, Y. Bar-Dayan, D. Ravid, R. Rachamani.
Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial.
Ann Intern Med, 128 (1998), pp. 982-988
[17.]
H.E. Lebovitz, T.B. Wiegmann, A. Cnaan, S. Shahinfar, D.A. Sica, V. Broadstone, et al.
Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria.
Kidney Int Suppl, 45 (1994), pp. S150-S155
[18.]
H.H. Parving, H. Lehnert, J. Brochner-Mortensen, R. Gomis, S. Andersen, P. Arner.
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
N Engl J Med, 345 (2001), pp. 870-878
[19.]
C.E. Mogensen, S. Neldam, I. Tikkanen, S. Oren, R. Viskoper, R.W. Watts, et al.
Randomized controlled trial of dual blockade of reninangiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan an lisinopril microalbuminuria (CALM) study.
BMJ, 321 (2000), pp. 1440-1444
[20.]
J.P. Garg, G.L. Bakris.
Microalbuminuia: marker of vascular dysfunction, risk factor for cardiovascular disease.
Vasc Med, 7 (2002), pp. 35-43
[21.]
M. Moser.
Current recomendations for the treatment of hypertension: are they still valid?.
J Hypertens, 20 (2002), pp. S3-S10
[22.]
P. Sleight.
The HOPE study (Heart Outcomes Prevention Evaluation).
J Renin Angiotensin Aldosterone Syst, 1 (2000), pp. 18-20
[23.]
P. Sleight.
Future perspectives and implications.
Int J Clin Pract, (2001), pp. 22-23
[24.]
J. Redon.
Renal protection by antihypertensive drugs: insights from microalbuminuria studies.
J Hypertens, 16 (1998), pp. 2091-2100
[25.]
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 39. UK Prospective Diabetes Study Group..
BMJ, 317 (1998), pp. 713-720
[26.]
H.L. Hillege, W.N. Janssen, A.A. Bak, G.F. Diercks, D.E. Grobbee, H.J. Crijns, et al.
Microalbuminuria is common, also in nondiabetic, nohipertensive population, and an independent indicator of cardiovascular risk factor and cardiovascular morbidity.
J Intern Med, 249 (2001), pp. 519-526
[27.]
G.L. Bakris.
Microalbuminuria: what is it? why is it important? what should be done about it?.
J Clin Hipertens (Greenwich), 3 (2001), pp. 99-102
Copyright © 2004. Elsevier España, S.L. y Sociedad Española de Medicina Rural y Generalista (SEMERGEN)
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.